b
r
c
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
frequent
develop
acut
respiratori
failur
arf
pulmonari
infiltr
molecularand
biomarkerbas
assay
enhanc
pathogen
detect
data
yield
popul
scarc
retrospect
singlecent
studi
consecut
hsct
recipi
admit
intens
care
unit
icu
may
juli
find
microbiolog
diagnost
workup
use
current
avail
method
bronchoalveolar
lavag
bal
blood
sampl
patient
age
year
rang
hsct
icu
day
rang
arf
pulmonari
infiltr
analyz
patient
caus
pathogen
identifi
fungal
n
viral
n
bacteri
n
polymicrobi
find
involv
sever
pathogen
group
occur
patient
cultur
galactomannan
aspergilluspcr
bal
serum
galactomannan
help
diagnos
invas
aspergillosi
n
aspergilluspcr
detect
azol
resist
case
mucoral
found
patient
bal
cultur
n
mucoralespcr
n
patient
identifi
pathogen
higher
simplifi
acut
physiolog
score
ii
score
p
inferior
icu
surviv
versu
p
larg
relat
presenc
invas
fungal
infect
eight
patient
virus
uncertain
lung
pathogen
sole
microbiolog
find
diagnost
microbiolog
workup
incorpor
molecularand
biomarkerbas
assay
identifi
pathogen
hsct
recipi
arf
pulmonari
infiltr
admit
icu
implic
polymicrobi
infect
pathogen
pattern
patient
warrant
investig
pulmonari
complic
signific
contributor
morbid
nonrelaps
mortal
allogen
hematopoiet
stem
cell
transplant
hsct
acut
respiratori
failur
arf
occur
patient
within
first
year
hsct
main
reason
intens
care
unit
icu
admiss
popul
broad
rang
possibl
caus
pathogen
noninfecti
process
dedic
algorithm
propos
determin
caus
pulmonari
infiltr
immunocompromis
host
cours
recent
decad
diagnost
test
becom
sophist
modern
approach
includ
molecular
eg
pcr
noncultur
test
eg
antigen
assay
detect
fungal
bacteri
andor
viral
pathogen
variou
type
specimen
addit
technic
advanc
list
respiratori
opportunist
virus
link
document
case
lower
respiratori
tract
diseas
immunocompromis
host
extend
last
year
develop
led
increas
number
diagnos
infect
hsct
recipi
arf
would
previous
diagnos
noninfecti
posthsct
lung
injuri
syndrom
fact
studi
abl
identifi
pathogen
half
case
previous
diagnos
idiopath
pneumonia
syndrom
use
molecular
noncultur
test
wide
array
pathogen
bronchoalveolar
lavag
bal
sampl
still
situat
remain
noninfecti
posthsct
lung
injuri
syndrom
becom
diagnosi
exclus
absenc
compar
data
literatur
studi
aim
first
analyz
find
modern
infect
detect
panel
perform
bal
blood
sampl
realworld
cohort
critic
ill
hsct
recipi
arf
pulmonari
infiltr
second
want
infer
possibl
clinic
scientif
implic
retrospect
studi
includ
consecut
adult
ie
year
old
hsct
recipi
treat
depart
bone
marrow
transplant
univers
hospit
essen
germani
studi
approv
ethic
committe
univers
duisburgessen
ec
conduct
accord
good
clinic
practic
guidelin
amend
declar
helsinki
center
perform
around
adult
hsct
per
year
inpati
unit
total
capac
bed
critic
ill
patient
treat
third
affili
unit
icu
provid
close
bed
run
train
intensivist
hematooncologist
consecut
adult
hsct
recipi
admit
icu
may
introduct
pcrbase
viral
panel
respiratori
specimen
test
juli
screen
includ
studi
cohort
bal
avail
result
perform
icu
stay
bal
conduct
part
workup
arf
new
requir
supplement
oxygen
ventilatori
support
hospit
pulmonari
infiltr
document
xray
comput
tomographi
ct
lung
day
procedur
data
shown
tabl
obtain
review
patient
medic
chart
radiograph
imag
discharg
letter
diseas
risk
categor
accord
seo
et
al
simplifi
acut
physiolog
score
ii
sapsii
use
assess
sever
ill
icu
admiss
absolut
neutrophil
count
absolut
lymphocyt
count
includ
result
avail
day
bal
standard
diagnost
test
perform
bal
includ
convent
cultur
bacteria
fungi
direct
microscopi
galactomannan
biorad
munich
germani
pcr
test
detect
fungal
maastricht
detect
mucoral
avail
januari
bal
test
perform
clinic
indic
tabl
result
blood
cultur
serum
cmv
serum
galactomannan
test
analyz
obtain
day
bal
result
galactomannan
test
bal
blood
report
posit
use
optic
densiti
index
viral
pathogen
grade
establish
uncertain
lung
pathogen
set
hsct
accord
seo
et
al
recoveri
candida
spp
enterococcu
spp
bal
report
absenc
posit
blood
cultur
document
diagnos
probabl
invas
aspergillosi
line
de
pauw
et
al
standard
antimicrobi
prophylaxi
consist
ciprofloxacin
metronidazol
condit
start
engraft
patient
prolong
neutropenia
system
corticosteroid
dose
mg
kg
bodi
weight
prednison
equival
receiv
antimold
prophylaxi
voriconazol
posaconazol
prophylaxi
p
jirovecii
use
trimethoprimsulfamethoxazol
pentamidin
well
antivir
prophylaxi
use
acyclovir
valaciclovir
follow
nation
guidelin
recommend
continu
data
present
median
interquartil
rang
iqr
dichotom
data
number
percentag
group
comparison
made
use
fisher
exact
test
mannwhitney
u
test
appropri
result
consid
statist
signific
p
exploratori
natur
studi
adjust
multipl
test
made
statist
test
perform
use
spss
softwar
packag
ibm
armonk
ny
hsct
recipi
admit
icu
may
juli
patient
men
women
age
year
iqr
fulfil
inclus
criteria
studi
figur
tabl
show
patient
characterist
regard
hsct
sever
ill
organ
support
measur
icu
outcom
icu
referr
occur
day
iqr
hospit
admiss
day
iqr
hsct
hospit
transplant
patient
bal
perform
day
iqr
icu
admiss
tabl
test
perform
respect
sampl
tabl
patient
present
multifoc
diffus
infiltr
chest
xray
n
wherea
focal
infiltr
quadrant
involv
iqr
chest
ct
day
bal
avail
patient
method
detect
infiltr
patient
neg
chest
xray
time
bal
patient
receiv
invas
mechan
ventil
time
intub
bal
day
iqr
patient
receiv
noninvas
ventil
via
face
mask
patient
receiv
highflow
nasal
cannula
oxygen
patient
receiv
convent
oxygen
therapi
patient
n
least
immunosuppress
agent
bal
perform
medic
data
avail
patient
tabl
transbronchi
biopsi
perform
patient
bacteri
pathogen
identifi
bal
specimen
patient
mostli
context
posit
cultur
growth
tabl
nonferment
stenotrophoma
maltophilia
n
pseudomona
aeruginosa
n
abund
bacteri
pathogen
alongsid
gramneg
bacilli
full
list
detect
pathogen
speci
given
figur
nearli
univers
coverag
antipseudomon
betalactam
antibiot
n
time
bal
concomit
blood
cultur
avail
patient
yield
noncontamin
bacteria
patient
patient
bacteria
detect
bal
also
posit
blood
cultur
tabl
fungi
repres
promin
pathogen
group
identifi
patient
belong
mold
speci
detect
posit
cultur
growth
tabl
fortyf
patient
receiv
moldact
antifung
agent
time
bal
consid
cultur
result
noncultur
test
bal
galactomannan
pcr
blood
galactomannan
diagnost
workup
provid
mycolog
evid
aspergillu
spp
patient
sixteen
patient
document
diagnosi
probabl
invas
aspergillosi
figur
show
sensit
give
inform
overal
test
perform
patient
overal
cohort
bal
cultur
posit
test
case
bal
galactomannan
case
respect
remaind
least
differ
posit
test
serum
galactomannan
posit
test
document
diagnosi
probabl
invas
aspergillosi
aspergillu
dnaposit
sampl
test
found
mutat
gene
confer
azol
resist
seven
patient
diagnos
invas
mucormycosi
patient
base
posit
cultur
growth
addit
patient
posit
pcr
check
establish
risk
factor
invas
mucormycosi
cohort
found
associ
relaps
diseas
tabl
pcrbase
panel
identifi
least
viral
pathogen
bal
specimen
patient
relat
number
test
conduct
cmv
abund
viru
follow
sever
virus
uncertain
lung
pathogen
hrv
adv
etc
tabl
median
cmv
dna
load
bal
copiesml
iqr
fifteen
patient
cmv
detect
bal
also
test
posit
viral
dna
plasma
highest
median
load
copiesml
iqr
wherea
patient
posit
blood
cmv
detect
viral
load
copiesml
bal
virus
establish
lung
pathogen
cmv
found
case
influenza
type
n
parainfluenza
viru
n
human
metapneumoviru
n
respiratori
syncyti
viru
n
eight
patient
virus
uncertain
lung
pathogen
identifi
sole
pathogen
bal
adv
n
n
hrv
n
human
bocaviru
n
varicella
zoster
viru
n
herp
simplex
viru
n
five
patient
diffus
groundglass
opac
main
ct
find
patient
patchi
alveolar
consolid
patient
ct
scan
focal
infiltr
chest
xray
twentysix
patient
overal
cohort
receiv
antivir
therapi
time
bal
regard
patient
baselin
characterist
donor
type
show
associ
identif
establish
viral
pathogen
p
supplementari
tabl
count
fungal
bacteri
pathogen
deem
like
caus
pneumonia
virus
establish
lung
pathogen
set
hsct
patient
least
pathogen
identifi
case
signific
pathogen
least
differ
group
could
found
figur
check
associ
pathogen
group
individu
pathogen
found
statist
signific
evid
supplementari
tabl
tabl
icu
surviv
patient
polymicrobi
infect
compar
patient
remaind
p
patient
virus
uncertain
lung
pathogen
sole
microbiolog
find
patient
surviv
icu
discharg
without
specif
antivir
therapi
patient
hrv
adv
respect
panelbas
multiplex
pathogen
test
design
achiev
rapid
turnaround
time
detect
larg
number
microorgan
increasingli
use
assist
diagnosi
respiratori
tract
infect
bloodstream
infect
other
immunocompromis
patient
particular
could
benefit
approach
broad
rang
pathogen
may
caus
clinic
present
popul
often
come
atyp
sign
symptom
first
studi
report
comprehens
find
diagnost
workup
includ
current
avail
panelbas
method
reallif
cohort
critic
ill
patient
arf
pulmonari
infiltr
hsct
found
around
patient
pathogen
known
caus
pneumonia
polymicrobi
find
frequent
addit
virus
uncertain
lung
pathogen
sole
microbiolog
find
fungi
commonli
detect
pathogen
microbiolog
evid
found
patient
preval
thu
appear
somewhat
higher
previous
report
noncrit
ill
hsct
recipi
pulmonari
infiltr
gener
popul
critic
ill
immunocompromis
patient
importantli
probabl
invas
aspergillosi
occur
despit
standard
prophylaxi
almost
univers
antimold
coverag
time
bal
sever
patient
least
case
associ
genotyp
azol
resist
respect
strain
insuffici
drug
level
azol
therapi
may
also
led
breakthrough
infect
respect
data
avail
analysi
regard
nonaspergillu
mold
infect
signific
proport
patient
suffer
invas
mucormycosi
broad
antimold
antifung
known
risk
factor
condit
although
risk
factor
preced
graftversushost
diseas
older
age
diseas
relaps
profound
neutropenia
also
taken
account
cohort
found
associ
mucormycosi
latter
statist
power
analysi
limit
emerg
azol
resist
increas
number
nonaspergillu
mold
infect
previous
describ
hsct
recipi
find
probabl
outlin
increas
complex
fungal
infect
pattern
hsct
popul
ultim
distribut
may
clinic
implic
regard
regimen
antifung
prophylaxi
empir
therapi
time
bal
nonintub
patient
noninvas
test
eg
galactomannan
fail
identifi
case
mucormycosi
azoleresist
aspergillu
strain
howev
studi
respect
warrant
importantli
even
within
cohort
high
baselin
immunosuppress
evid
impair
immun
reconstitut
indic
low
absolut
lymphocyt
count
highdos
corticosteroid
therapi
help
identifi
individu
highest
risk
invas
fungal
diseas
second
common
pathogen
group
virus
detect
bal
sampl
patient
implement
broad
viral
pcr
panel
cmv
abund
viru
detect
viral
load
copiesml
everi
third
patient
although
cutoff
recent
establish
support
diagnosi
cmv
pneumonia
context
hsct
patient
respect
clinic
diagnosi
document
howev
even
absenc
overt
diseas
subclin
cmv
infect
lung
shown
produc
signific
biolog
effect
inflamm
fibrosi
similar
consider
appli
patient
find
virus
uncertain
lung
pathogen
although
sever
virus
human
coronaviru
hrv
increasingli
recogn
caus
lower
respiratori
tract
diseas
hsct
evid
accumul
varieti
subclin
pathogen
process
induc
lung
upon
infect
virus
although
research
host
respons
need
studi
includ
newer
antivir
agent
focus
prevent
strategi
patient
asymptomat
shed
upper
respiratori
tract
diseas
alreadi
ongo
given
infer
high
rate
polymicrobi
find
patient
see
strategi
may
suit
improv
outcom
intervent
patient
alreadi
develop
arf
support
studi
bacteri
pathogen
detect
bal
sampl
patient
clear
predomin
gramneg
bacilli
older
patient
age
time
hsct
icu
admiss
factor
associ
identif
bacteri
pathogen
wherea
time
hospit
icu
admissiona
possibl
surrog
acquisit
hospitalacquir
pneumoniadid
correl
find
data
shown
previou
exposur
antibiot
well
hospit
would
variabl
interest
context
could
obtain
respect
data
interestingli
time
hsct
icu
admiss
correl
detect
pathogen
group
polymicrobi
find
almost
third
case
anoth
import
observ
studi
although
polymicrobi
pneumonia
clinic
diagnosi
patient
probabl
clinician
attribut
lung
injuri
pattern
specif
pathogen
accord
patient
histori
clinic
assess
radiograph
find
howev
clinic
assess
radiograph
find
lack
specif
mani
instanc
hand
outlin
cmv
microbiolog
find
may
still
signific
even
seem
account
predomin
pattern
lung
injuri
henc
mutual
interact
pathogen
inher
pathogen
act
compet
condit
could
signific
promot
lung
injuri
patient
case
observ
frequent
polymicrobi
find
would
import
reduc
chanc
singl
pathogendirect
intervent
success
either
clinic
practic
clinic
trial
detect
caus
pathogen
enhanc
diagnost
certainti
guid
antimicrobi
therapi
furthermor
inabl
identifi
caus
arf
hematolog
patient
independ
factor
associ
mortal
although
analysi
outcom
measur
scope
studi
find
increas
mortal
patient
detect
pathogen
therefor
surpris
howev
similar
observ
made
studi
seo
et
al
three
factor
may
account
observ
first
invas
fungal
infect
associ
excess
mortal
hsct
recipi
detect
rate
high
inde
patient
invas
fungal
infect
cohort
surviv
icu
discharg
second
even
respect
hsct
patient
cohort
highli
immunosuppress
multiag
immunosuppress
therapi
includ
corticosteroid
shown
low
absolut
lymphocyt
count
detect
pathogen
may
therefor
deleteri
patient
significantli
impair
infect
control
capabl
especi
regard
possibl
consequ
high
pathogen
burden
third
patient
detect
pathogen
sever
ill
without
howev
may
regard
either
consequ
respect
pathogen
factor
influenc
detect
rate
patient
major
strength
studi
includ
reason
number
patient
contemporari
cohort
hsct
recipi
admit
icu
find
may
thu
reflect
current
pattern
observ
popul
hand
microbiolog
find
regard
pathogen
occurr
resist
alway
follow
local
condit
therebi
put
place
retrospect
observ
natur
studi
sever
technic
aspect
standard
conduct
bal
uniform
sampl
process
ensur
limit
relat
studi
design
concern
data
complet
qualiti
interpret
final
studi
provid
mere
descript
microbiolog
find
allow
infer
rel
contribut
singl
pathogen
arf
outcom
conclus
use
microbiolog
diagnost
workup
incorpor
molecularand
biomarkerbas
assay
bal
blood
sampl
pathogen
known
caus
pneumonia
found
hsct
recipi
arf
admit
icu
addit
viru
undetermin
lung
pathogen
sole
microbiolog
find
bal
may
enhanc
pathogen
detect
therapi
guidanc
set
high
preval
invas
mold
infect
includ
nonaspergillu
strain
emerg
azol
resist
polymicrobi
find
almost
third
patient
warrant
consider
clinic
practic
design
futur
intervent
studi
